Psychometric Properties of the Beliefs About Medicine Questionnaire-adjuvant Endocrine Therapy (BMQ-AET) for Women Taking AETs Following Early-stage Breast Cancer

Overview

Journal Health Psychol Open

Publisher Sage Publications

Specialty Psychology

Date 2018 Jan 31

PMID 29379627

Citations 9

Authors

Jo Brett

Nick J Hulbert-Williams

Deborah Fenlon

Mary Boulton

Fiona M Walter

Peter Donnelly

Bernadette Lavery

Adrienne Morgan

Carolyn Morris

Rob Horne

Eila Watson

Affiliations

Soon will be listed here.

Abstract

This study evaluated the Beliefs about Medicine Questionnaire to explore adherence to adjuvant endocrine therapy after treatment for breast cancer (BMQ-AET). Factor structure of the BMQ-AET was explored alongside internal consistency, convergent validity and acceptability. The BMQ-AET Specific Scale fitted the original 10 item model. Internal consistency of the BMQ-AET was much improved compared to the original BMQ and convergent validity showed predicted direction of correlation, although correlation with BMQ-AET concerns scale was low. Acceptability was good. The evaluation of the BMQ-AET is encouraging, and could facilitate future research around adherence to AET.

Citing Articles

Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial.

Smith S, Green S, McNaught E, Graham C, Foy R, Loo Ow P Ann Behav Med. 2025; 59(1).

PMID: 39887069 PMC: 11783298. DOI: 10.1093/abm/kaaf003.

Dataset for a randomised factorial experiment to optimise an information leaflet for women with breast cancer.

Green S, Smith S NIHR Open Res. 2024; 4:32.

PMID: 39145099 PMC: 11320031. DOI: 10.3310/nihropenres.13547.1.

Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.

ONeil D, Blanchard C, Joffe M, Antoni M, Ream M, Mmoledi K Res Sq. 2024; .

PMID: 38978566 PMC: 11230477. DOI: 10.21203/rs.3.rs-4559587/v1.

Decision-making in the multiphase optimization strategy: Applying decision analysis for intervention value efficiency to optimize an information leaflet to promote key antecedents of medication adherence.

Green S, Smith S, Collins L, Strayhorn J Transl Behav Med. 2024; 14(8):461-471.

PMID: 38795061 PMC: 11282575. DOI: 10.1093/tbm/ibae029.

Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.

Green S, Hall L, French D, Rousseau N, Parbutt C, Walwyn R Ann Behav Med. 2023; 57(11):988-1000.

PMID: 37494669 PMC: 10578395. DOI: 10.1093/abm/kaad037.

References

Horne R, Weinman J . Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 2000; 47(6):555-67. DOI: 10.1016/s0022-3999(99)00057-4. View

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2009; 28(3):509-18. DOI: 10.1200/JCO.2009.23.1274. View

Llewellyn C, McGurk M, Weinman J . Are psycho-social and behavioural factors related to health related-quality of life in patients with head and neck cancer? A systematic review. Oral Oncol. 2005; 41(5):440-54. DOI: 10.1016/j.oraloncology.2004.12.006. View

Brown C, Battista D, Bruehlman R, Sereika S, Thase M, Dunbar-Jacob J . Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care. 2005; 43(12):1203-7. DOI: 10.1097/01.mlr.0000185733.30697.f6. View

Hadji P . Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2009; 73(2):156-66. DOI: 10.1016/j.critrevonc.2009.02.001. View

Horne R, Chapman S, Parham R, Freemantle N, Forbes A, Cooper V . Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013; 8(12):e80633. PMC: 3846635. DOI: 10.1371/journal.pone.0080633. View

Forbes J, Cuzick J, Buzdar A, Howell A, Tobias J, Baum M . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2007; 9(1):45-53. DOI: 10.1016/S1470-2045(07)70385-6. View

McCowan C, Shearer J, Donnan P, Dewar J, Crilly M, Thompson A . Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99(11):1763-8. PMC: 2600703. DOI: 10.1038/sj.bjc.6604758. View

Terwee C, Bot S, de Boer M, van der Windt D, Knol D, Dekker J . Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2006; 60(1):34-42. DOI: 10.1016/j.jclinepi.2006.03.012. View

10.

Llewellyn C, McGurk M, Weinman J . Illness and treatment beliefs in head and neck cancer: is Leventhal's common sense model a useful framework for determining changes in outcomes over time?. J Psychosom Res. 2007; 63(1):17-26. DOI: 10.1016/j.jpsychores.2007.01.013. View

11.

Banning M . Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl). 2011; 21(1):10-9. DOI: 10.1111/j.1365-2354.2011.01295.x. View

12.

Gotay C, Dunn J . Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011; 11(6):709-15. DOI: 10.1586/erp.11.80. View

13.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365(9453):60-2. DOI: 10.1016/S0140-6736(04)17666-6. View

14.

Thompson K, Kulkarni J, Sergejew A . Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000; 42(3):241-7. DOI: 10.1016/s0920-9964(99)00130-9. View

15.

Salgado T, Marques A, Geraldes L, Benrimoj S, Horne R, Fernandez-Llimos F . Cross-cultural adaptation of The Beliefs about Medicines Questionnaire into Portuguese. Sao Paulo Med J. 2013; 131(2):88-94. PMC: 10871720. DOI: 10.1590/s1516-31802013000100018. View

16.

Hershman D, Kushi L, Shao T, Buono D, Kershenbaum A, Tsai W . Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28(27):4120-8. PMC: 2953970. DOI: 10.1200/JCO.2009.25.9655. View

17.

Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97(17):1262-71. DOI: 10.1093/jnci/dji250. View

18.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012; 381(9869):805-16. PMC: 3596060. DOI: 10.1016/S0140-6736(12)61963-1. View

19.

van Dulmen S, Sluijs E, van Dijk L, Ridder D, Heerdink R, Bensing J . Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007; 7:55. PMC: 1955829. DOI: 10.1186/1472-6963-7-55. View

20.

Wouters H, van Geffen E, Baas-Thijssen M, Krol-Warmerdam E, Stiggelbout A, Belitser S . Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence. Breast. 2013; 22(5):661-6. DOI: 10.1016/j.breast.2013.05.005. View